New pill for brain disorders takes first safety step
NCT ID NCT06300398
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new oral drug called IAMA-6 in 72 healthy adults to see if it is safe and how the body processes it. The drug is being developed for neurodevelopmental disorders, but this trial did not treat any disease. Researchers monitored side effects, vital signs, and lab results to gather initial safety data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEURODEVELOPMENTAL DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centro Ricerche Cliniche Di Verona S.r.l.
Verona, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple gum reshape baby brain health? a new study investigates
- Do weighted blankets unlock better sleep for kids with ADHD?
- Could a phone app help parents of kids with special needs thrive?
- Could a Self-Help guide transform parenting stress for families of kids with NDD?
- Can Early-Life factors steer preterm and term infant health?
- Video game trains the brain to focus — could it help neurodevelopmental disorders?